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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: Surfactant is a useful vehicle for the intratracheal delivery of medicine to the
distal lung. The aim of this study was to analyze the effect of intratracheal surfactant and bu-
desonide instillation on the pulmonary distribution of fluorescent dye in mice.
Methods: Male athymic nude mice were assigned randomly as controls, fluorescent dye, fluo-
rescent dye þ surfactant (50 mg/kg), fluorescent dye þ budesonide (0.25 mg/kg), and fluores-
cent dye þ surfactant þ budesonide groups. A total volume of 60 mL fluorescent solutions was
intratracheally injected and followed by 60 mL of air. We photographed and measured fluores-
cence in the lungs, from the back, 15 minutes after intratracheal administration using an IVIS
Xenogen imaging instrument.
Results: The fluorescent dye (1,10-dioctadecyltetramethyl indotricarbocyanine iodide) was
most strongly detected near the trachea and weakly detected in the lungs in mice adminis-
tered with fluorescent solutions. Almost no fluorescence was seen in the lung region of con-
trol mice. Intratracheal administration of surfactant or budesonide increased fluorescent
intensity compared with control mice. Combined administration of surfactant and budeso-
nide further increased fluorescent intensity compared with mice given surfactant or budeso-
nide alone.of Pediatrics, Taipei Medical University Hospital, 252 Wu-Hsing Street, Taipei, Taiwan.
tw (C.-M. Chen).
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reserved.1. Introduction
Respiratory distress syndrome (RDS) is a major cause of
morbidity and mortality in preterm infants, especially
among infants with extremely low birth weight.1 Despite
recent improvements in treating RDS in preterm infants,
bronchopulmonary dysplasia (BPD) remains a major cause
of morbidity and mortality during the 1st year of life. Many
affected infants continue to endure significant respiratory
problems throughout childhood, including increased airway
reactivity and the development of obstructive airway dis-
ease.1 Surfactant therapy has become the standard of care
in preterm infants with RDS, and it has been shown to
reduce the combined outcomes of death and BPD in pre-
term infants with RDS.2,3
The pathogenesis of BPD is multifactorial, but pulmonary
inflammation is thought to play an important role in the
lung injury process that leads to the development of BPD.4
Clinical trials have shown that systemic application of
postnatal corticosteroid therapy improves short-term lung
function and the outcome of BPD, and reduces the risk of
BPD in high-risk preterm infants. However, systemic corti-
costeroid administration is associated with serious adverse
effects.5e7 Because of these side effects, the American
Academy of Pediatrics discourages the use of postnatal
corticosteroids for the treatment of BPD.8 Corticosteroids
may alleviate pulmonary inflammation. If the local anti-
inflammatory effect on the lung can be used while the
systemic side effects are curtailed, corticosteroids can be
extremely useful in preventing BPD. Pulmonary delivery of
the drug to the lung may reduce unwanted systemic ac-
tivity. Surfactant is a mixture of lipids and several specific
surfactant proteins, which have a unique spreading prop-
erty and reduce surface tension. These characteristics are
ideal for a carrier of choice to instil therapeutic agents into
the lung. Previous research has suggested that a surfactant
may provide a useful vehicle for the intratracheal delivery
of medicine to the distal lung.9 The combined administra-
tion of intratracheal surfactant and corticosteroids has an
anti-inflammatory effect in animal models of acute lung
injury and RDS.10e12 To monitor real-time drug delivery,
this study used an in vivo imaging system to analyze the
effect of intratracheal surfactant and budesonide instilla-
tion on the pulmonary distribution of fluorescent dye.
2. Materials and methods
2.1. Animal preparations
Male athymic nude mice (nu/nu, aged 7e10 weeks, and
weighing 18e22 g each) were maintained in a pathogen-free facility. Animals were kept at approximately 25C and
pelleted food and water were available ad libitum
throughout the experiment. The study protocol was
approved by the Institutional Animal Care and Use Com-
mittee of Taipei Medical University.2.2. Preparation of the fluorescent dye solutions
XenoLight DiR (1,10-dioctadecyltetramethyl indo-
tricarbocyanine iodide) was obtained from Caliper Life-
Sciences (Hopkinton, MA, USA). The absorption and
emission wavelengths of XenoLight DiR were 748 nm and
780 nm, respectively. The fluorescent dye was prepared by
dissolving 25 mg XenoLight DiR in 2.5 mL ethanol as a stock
solution, which was then protected from light.2.3. Intratracheal instillation of the fluorescent dye
solutions
For intratracheal administration, mice were anesthetized
with an intraperitoneal injection of pentobarbital (10 mg/
kg). They were then positioned against an angled
restraining stand and exposed to locate the trachea. The
fluorescent dye solutions were prepared and mixed imme-
diately before intratracheal instillation. Survanta (Abbott,
Columbus, OH, USA) and budesonide (AstraZeneca, Lund,
Sweden) were given intratracheally at dosages of 50 mg/kg
and 0.25 mg/kg, respectively. The budesonide dosage
(0.25 mg/kg) was based on a clinical study which showed
that mixing a surfactant suspension (0.25 mg/kg of bude-
sonide and 100 mg/kg of Survanta) improved the combined
outcome of death or chronic lung disease in small prema-
ture infants.13
Mice were randomly assigned to five treatment groups
(n Z 6 per group), as follows: control [60 mL phosphate
buffered saline (PBS)]; fluorescent dye (3 mL XenoLight DiR,
7 mL ethanol, and 50 mL PBS); fluorescent dye and surfac-
tant (3 mL XenoLight DiR, 7 mL ethanol, 40 mL Survanta, and
10 mL PBS); fluorescent dye and budesonide (3 mL XenoLight
DiR, 7 mL ethanol, 10 mL budesonide, and 40 mL PBS); and
fluorescent dye, surfactant, and budesonide (3 mL Xeno-
Light DiR, 7 mL ethanol, 40 mL Survanta, and 10 mL bude-
sonide). Each group contained six mice. A total volume of
60 mL fluorescent solution was instilled intratracheally
through a plastic blunt cannula with a 1.20-mm gauge
diameter, followed by 60 mL of air. The Survanta and
budesonide doses are fixed based on mouse body weight
(20 g). Survanta: 50 mg/kg  0.02 kg Z 1 mg Z 40 mL
Survanta (25 mg/mL); budesonide: 0.25 mg/
kg  0.02 kgZ 0.005 mgZ 10 mL budesonide (0.5 mg/mL).
Budesonide on Lung Distribution of Fluorescent Dye 212.4. Measurement of surface tension
The static contact angles characterizing surface tension of
fluorescent dye solutions were measured by the sessile drop
method resting on polytetrafluoroethylene using a Magic
Droplet Model 100SB Video Contact Angle System (Sindatek
Instruments Co. Ltd., Taipei, Taiwan). To minimize the
interaction between fluorescent dye solutions and solid
substrates, the low intermolecular forces present in poly-
tetrafluoroethylene were used to account for the relatively
low surface free energy (surface tension Z 20 mN/m).14
Each measurement was repeated 10 times by dispensing a
uniform drop of 4-mL solutions at 20C. Surface tension was
determined from the contact angle and equation, g cos
qZ g þ 46.85, where g is the surface tension and q is the
contact angle.15,16
2.5. Monitoring of pulmonary distribution using
fluorescent imaging
Fluorescent imaging of mice was performed using an IVIS-
200 small animal imaging system (Caliper LifeSciences,
Hopkinton, MA, USA). The measurements were taken from
the back of the animals. During imaging, the mice were
kept on the stage under anesthesia with isoflurane gas.
Indocyanine green (ICG) excitation (lex Z 705e780 nm)
and ICG emission (lem Z 810e885 nm) filters were used.
Identical illumination settings were used for all image
acquisition, namely exposure time (1 second), binning
factor (8), f-stop (2), and fields of view (25  25 cm).
Fluorescent and photographic images were acquired and
overlaid. The pseudocolor image represents the spatial
distribution of photon counts within the organs. Background
fluorescence was subtracted prior to analysis. Fluorescent
intensity in the lung fields was quantified using Xenogen
Living Image 2.5 software (Caliper Life Sciences, Hopkin-
ton, MA, USA).
2.6. Statistical analysis
Data are presented as mean  standard deviation. Statis-
tically significant differences were analyzed using one-way
analysis of variance with post hoc Bonferroni test. Differ-
ences were considered significant if the relevant p values
were <0.05.
3. Results
3.1. Surface tension of fluorescent dye solutions
The surface tensionswere105.2 2.0mN/m,120.7 4.2mN/
m, 57.2 1.3 mN/m, 57.9 1.2 mN/m, and 53.6 1.8 mN/m
in the control (PBS), fluorescent dye, fluorescent
dye þ surfactant, fluorescent dye þ budesonide, and fluo-
rescent dye þ surfactant þ budesonide groups, respectively.
Fluorescent dyeþ surfactant, fluorescent dyeþ budesonide,
and fluorescent dye þ surfactant þ budesonide solutions
exhibited significantly lower surface tension compared to PBS
and fluorescent dye solutions (p < 0.001). Fluorescent
dyeþ surfactantþbudesonidesolutionexhibited significantlylower surface tension compared to fluorescent
dye þ surfactant and fluorescent dye þ budesonide solutions
(p < 0.01).
3.2. Pulmonary distribution of fluorescent dye
solutions
Fluorescent dye was administered to mice through an
intratracheal injection. Fifteen minutes after the injection,
the amount of fluorescent dye in the lungs of the mice was
measured to visualize and evaluate the pulmonary distri-
bution of the dye. As shown in Figure 1, fluorescence in the
lungs was most strongly detected near the trachea
(measured from the back of the mice). Almost no fluores-
cence was seen in the lung region of the control mice.
Compared with the control group, the fluorescent intensity
observed in the experimental groups increased by the
following percentages: in the fluorescent dye group, 2%; in
the fluorescent dye þ surfactant group, 57%; in the fluo-
rescent dye þ budesonide group, 34%; and in the fluores-
cent dye þ surfactant þ budesonide group, 100% (Figure 2).
Mice treated with either surfactant or budesonide exhibited
an approximately 30% increase in fluorescent intensity
compared with mice that received fluorescent dye alone.
No significant difference was found between the fluores-
cent dye þ surfactant and the fluorescent
dye þ budesonide groups. Mice treated with both surfac-
tant and budesonide showed a significant increase in fluo-
rescent intensity compared with mice treated with either
surfactant or budesonide alone.
To obtain more detailed results, we opened the chest
and removed the lungs and heart en bloc from the mice
immediately after fluorescence measurement. As shown in
Figure 3, the fluorescence was most strongly detected in
the lungs, indicating a direct delivery of dye to the lungs.
Furthermore, the fluorescence increased, after the chest
was opened, in the lungs of the mice that received fluo-
rescent dye solutions. These results suggested that the
skeleton of the chest prevented fluorescence in the lungs.
4. Discussion
In this study we evaluated the effect of intratracheal
administration of surfactant and budesonide on the pul-
monary distribution of fluorescent dye in mice. This
research was necessary because previous studies have
found that the systemic administration of corticosteroids
leads to complications.5e7 We found that intratracheal
administration of surfactant or budesonide increased the
fluorescent intensity in the lungs of mice, compared with
the control condition. The combined intratracheal admin-
istration of surfactant and budesonide further increased
the fluorescent intensity relative to the administration of
either surfactant or budesonide alone.
The use of surfactants as a vehicle to deliver steroid to
the lungs has been investigated in small animal models.17,18
However, the results were not constant, and temporal and
spatial information could not be attained. Fajardo et al17
found that both surfactant and saline solution provided an
efficient delivery of radiolabeled budesonide to the lungs of
rabbits, with the solutions being equally effective. They
Figure 1 Representative image of the pulmonary distribution of fluorescent dye in mice. Fluorescence was most strongly
detected in the lungs of mice administered fluorescent dye þ surfactant, fluorescent dye þ budesonide, and fluorescent
dye þ surfactant þ budesonide and was not detected in the control mice.
22 L.-T. Huang et alsuggested that either surfactants or saline could be used to
efficiently and reliably deliver corticosteroid to the lungs.17
Nimmo et al18 investigated the delivery of radiolabeled
dexamethasone in surfactant by intratracheal instillation in
rats, and they found that the dexamethasone was well0
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Figure 2 Quantification of fluorescent activity in the lungs of
mice. The scale is in photons/s/cm2/sr. In mice administered
surfactant or corticosteroid, there was an approximately 30%
increase in fluorescent activity compared with mice adminis-
tered fluorescent dye alone. There was no difference in
fluorescence between the fluorescent dye þ surfactant and
fluorescent dye þ budesonide groups. Mice administered
surfactant and corticosteroid exhibited an approximately 30%
increase in fluorescent activity compared with mice adminis-
tered surfactant or corticosteroid. ))p < 0.05, )))p < 0.01
versus control and fluorescent dye groups. yp < 0.05 versus
fluorescent dye þ surfactant and fluorescent dye þ budesonide
groups; n Z 6 per group.distributed throughout all four lobes of the lungs; a con-
centration gradient was observed between the root and
periphery of each lobe.18 Nimmo et al18 concluded that
delivery was more effective and consistent using the sur-
factant rather than saline as a vehicle.
The surface tension of fluorescent dye solution was
higher than other solutions and the addition of surfactant
and/or budesonide significantly decreased the surface
tension. The surface tensions of fluorescent
dye þ surfactant and fluorescent dye þ budesonide solu-
tions were not statistically significantly different. Budeso-
nide suspension is a sterile suspension for inhalation via
nebulizer and contains the active ingredient budesonide,
and the inactive ingredients citric acid, edetate disodium
dihydrate, polysorbate 80, sodium chloride, sodium citrate,
and water. A water-insoluble suspension of budesonide was
sterically stabilized using polysorbate 80.19 Polysorbate 80
is a nonionic surfactant and emulsifier derived from poly-
ethoxylated sorbitan and oleic acid. Disodium edetate is a
parenteral chelating agent. Polysorbate 80 and disodium
edetate have the ability to reduce surface tension.20,21
Real-time in vivo fluorescent imaging provides useful
technology for studying drug deposition in tissues. In ani-
mal models, temporal and spatial information can be
collected by fluorescent dye studies.22 The in vivo imaging
system also provides the advantages of not requiring radi-
ation and being easy to operate; furthermore it offers a
noninvasive insight into living organisms. In this study, we
found that the administration of surfactant and budesonide
increases fluorescent intensity, although budesonide was
not labeled. XenoLight DiR is a lipophilic, near-infrared
fluorescent cyanine dye, which is ideal for staining the
cytoplasmic membrane. Both surfactant and budesonide
are also lipid-soluble and attach to fluorescent dye. We
speculated that these features would make surfactant and
Figure 3 Ex vivo tissue imaging: excised lung tissues from representative fluorescence administered and control mice. These
changes in ex vivo fluorescence confirm the dramatic increase in fluorescence signal in the lungs quantified using an IVIS Xenogen
imaging instrument (Caliper LifeSciences). Excised lung tissues were assessed for fluorescence changes, with images revealing
significant increases in lung fluorescence intensity in the mice administered surfactant and corticosteroid and was not detected in
the control mice.
Budesonide on Lung Distribution of Fluorescent Dye 23budesonide easily distributed as fluorescent dye to the
lungs. Pulmonary surfactant is secreted by the alveolar
cells of the lung and serves to maintain the stability of
pulmonary tissue by reducing the surface tension of fluids
that coat the lung.23,24 Surfactants consist of an aqueous
dispersion of a mixture of lipids and proteins. The compo-
sition is almost 90% lipid, with the remaining 10% composed
of a mixture of proteins. Budesonide is also lipid soluble
because it has a similar structure to cholesterol. These
features allow both surfactant and budesonide to bind to
the fluorescent dye. In addition, both surfactant and
budesonide display a higher affinity for lung tissue.25,26
These characteristics might have resulted in a wider dis-
tribution of fluorescent dye in the fluorescent
dye þ surfactant and fluorescent dye þ budesonide groups,
relative to the fluorescent dye group. This study was not
performed on premature infants in the animal model. The
lungs of premature infants have microscopically confirmed
patchy atelectasis that may induce a nonhomogeneous
distribution of surfactant.27 Caution must therefore be
applied when extrapolating the results to premature
human infants.
In this study, we prepared and mixed the fluorescent dye
solutions immediately before intratracheal instillation.
Surfactant has been shown to increase the dissolution rate
of budesonide, with the effect being dose-dependent.28
Our procedure entailed the complete dissolution of the
fluorescent dye, surfactant, and budesonide. The surfac-
tant dosage (50 mg/kg) used in this study was half of that
used in the clinical studies (100 mg/kg) because of the
small lung volume in mice. This finding suggests that lungsurfactants may enhance the extent of distribution of a
drug administered to the lung.
5. Conclusion
We demonstrated that surfactant and budesonide
enhanced the pulmonary distribution of fluorescent dye in
mice. The in vivo imaging method was suitable for mini-
mally invasive testing of the efficacy of pulmonary drug
distribution.
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